- Home
- MTVA vs AIHS Comparison
MTVA vs AIHS Comparison
Compare MTVA & AIHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTVA
- AIHS
- Stock Information
- Founded
- MTVA 2014
- AIHS 2014
- Country
- MTVA United States
- AIHS China
- Employees
- MTVA N/A
- AIHS N/A
- Industry
- MTVA
- AIHS Finance: Consumer Services
- Sector
- MTVA
- AIHS Finance
- Exchange
- MTVA NYSE
- AIHS Nasdaq
- Market Cap
- MTVA 14.3M
- AIHS 11.9M
- IPO Year
- MTVA N/A
- AIHS 2018
- Fundamental
- Price
- MTVA $0.71
- AIHS $0.25
- Analyst Decision
- MTVA Strong Buy
- AIHS
- Analyst Count
- MTVA 2
- AIHS 0
- Target Price
- MTVA $7.50
- AIHS N/A
- AVG Volume (30 Days)
- MTVA 64.8K
- AIHS 259.0K
- Earning Date
- MTVA 08-13-2025
- AIHS 08-13-2025
- Dividend Yield
- MTVA N/A
- AIHS N/A
- EPS Growth
- MTVA N/A
- AIHS N/A
- EPS
- MTVA N/A
- AIHS N/A
- Revenue
- MTVA N/A
- AIHS $3,389,072.00
- Revenue This Year
- MTVA N/A
- AIHS N/A
- Revenue Next Year
- MTVA N/A
- AIHS N/A
- P/E Ratio
- MTVA N/A
- AIHS N/A
- Revenue Growth
- MTVA N/A
- AIHS N/A
- 52 Week Low
- MTVA $0.60
- AIHS $0.25
- 52 Week High
- MTVA $4.36
- AIHS $1.70
- Technical
- Relative Strength Index (RSI)
- MTVA N/A
- AIHS 28.82
- Support Level
- MTVA N/A
- AIHS $0.30
- Resistance Level
- MTVA N/A
- AIHS $0.33
- Average True Range (ATR)
- MTVA 0.00
- AIHS 0.02
- MACD
- MTVA 0.00
- AIHS 0.02
- Stochastic Oscillator
- MTVA 0.00
- AIHS 0.00
About MTVA METAVIA INC
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.
About AIHS Senmiao Technology Limited
Senmiao Technology Ltd is a holding company. The company's operating segment includes Automobile Transaction and Related Services focusing on the online ride-hailing industry in the People's Republic of China and Online ride-hailing platform Services through its own platform, Xixingtianxia. It generates maximum revenue from the Automobile Transaction and Related Services segment. Geographically, it derives revenue from China.